Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of WAL0921 in Patients With Glomerular Kidney Diseases and Proteinuria

Next Previous
Trial Profile

Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of WAL0921 in Patients With Glomerular Kidney Diseases and Proteinuria

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs WAL 0921 (Primary)
  • Indications Diabetic neuropathies; Focal segmental glomerulosclerosis; IgA nephropathy; Kidney disorders; Lipoid nephrosis; Membranous glomerulonephritis; Proteinuria
  • Focus Adverse reactions
  • Sponsors Walden Biosciences

Most Recent Events

  • 10 Jan 2025 According to an Walden Biosciences media release, interim data on WAL0921-02 in Rare glomerular kidney diseases expected in 2025.
  • 10 Jan 2025 According to an Walden Biosciences media release, company announced Full Enrollment in the Second Cohort.comapny plan toInitiate the third Cohort of the Phase 2 Basket study (WAL0921-02) in Rare glomerular kidney diseases, including focal segmental glomerulosclerosis (FSGS), treatment resistant minimal change disease (TR-MCD), IgA nephropathy (IgAN), and primary membranous nephropathy (PMN) in 2025.
  • 10 Jan 2025 According to an Walden Biosciences media release, Initial dosing from the first two Cohorts evaluating Waldens anti-suPAR antibody in patients with diabetic nephropathy is complete and fully supports continued enrollment in the studys Rare kidney disease patient population.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top